Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028130 | 1.00 | MAPT (0.60) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL4163112 | 0.84 | MAPT (0.60) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL7827616 | 0.78 | MAPT (0.52) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL7587270 | 0.77 | POLB (0.50) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL11027188 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11027185 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11025705 | 0.74 | MAPT (0.53) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11030281 | 0.73 | ALDH1A1 (0.46) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11025683 | 0.73 | ALDH1A1 (0.52) | MAPTALDH1A1HTTAGTR1MEN1 | |
| SCHEMBL11025717 | 0.73 | ALDH1A1 (0.52) | MAPTALDH1A1HTTAGTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190723-A1 | VIRAL MODULATORS AND PROCESSES THEREOF | KASHANCHI FATAH (US) | 2012-07-26 | — | — | US | claimed |
| US-20120190009-A1 | Viral Modulators and Processes Thereof | KASHANCHI FATAH (US) | 2012-07-26 | — | — | US | claimed |
| US-20120190723-A1 | VIRAL MODULATORS AND PROCESSES THEREOF | KASHANCHI FATAH (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190009-A1 | Viral Modulators and Processes Thereof | KASHANCHI FATAH (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190723-A1 | VIRAL MODULATORS AND PROCESSES THEREOF | MAVS, HAVCR2, HDLBP | MAPT 1778/4885ALDH1A1 4453/4885HTT 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.